3 benefits for the intestines – prebiotic, probiotic, postbiotic Review article
Article Sidebar
Published:
Jun 30, 2024
Keywords:
prebiotic, probiotic, postbiotic, intestinal diseases
Main Article Content
Abstract
Intestinal diseases, both functional and inflammatory, are becoming a global health problem. Their etiology is multifactorial, diagnostics can be difficult and complex and is aimed not only at confirming the diagnosis, but also at excluding, above all, organic changes. The spectrum of ailments, especially in functional disorders, is wide and unstable, which is why we use symptomatic treatment, focused on the patient’s current ailments. One of the important causes is the disruption of the brain-gut axis, which translates into the functioning of the intestinal microbiota. Appropriate care for the microbiome, the use of prebiotics and postbiotics to maintain its balance, and supplementation with a properly tested probiotic are key elements of maintaining intestinal homeostasis.
Article Details
How to Cite
Waśko-Czopnik, D. (2024). 3 benefits for the intestines – prebiotic, probiotic, postbiotic. Medycyna Faktow (J EBM), 17(2(63), 204-208. https://doi.org/10.24292/01.MF.0224.06
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Ford AC, Lacy BE, Talley NJ. Irritable bowel syndrome. N Engl J Med. 2017; 376: 2566-78.
2. Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol. 2014; 6: 71-80.
3. Bhattarai Y, Muniz Pedrogo DA, Kashyap PC. Irritable bowel syndrome: A gut microbiota-related disorder? Am J Physiol Gastrointest Liver Physiol. 2017; 312: G52-62.
4. Mari A, Baker FA, Mahamid M et al. The evolving role of gut microbiota in the management of irritable bowel syndrome: An overview of the current knowledge. J Clin Med. 2020; 9: 685.
5. Weiss GA, Hennet T. Mechanisms and consequences of intestinal dysbiosis. Cell Mol Life Sci. 2017; 74: 2959-77.
6. Spiegel BM, Farid M, Esrailian E et al. Is Irritable bowel syndrome a diagnosis of exclusion? A survey of primary care providers, gastroenterologists, and IBS experts. Am J Gastroenterol. 2010; 105: 848-58.
7. Sperber AD, Bangdiwala SI, Drossman DA et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation global study. Gastroenterology. 2020; 160: 99-114.
8. Zhou SY, Gillilland M, Wu X et al. FODMAP diet modulates visceral nociception by lipopolysaccharide-mediated intestinal inflammation and barrier dysfunction. J Clin Investig. 2018; 128: 267-80.
9. Pietrzak A, Skrzydło-Radomańska B, Mulak A et al. Guidelines on the management of irritable bowel syndrome. Gastroenterology Rev. 2018; 13(4): 167-96.
10. Babicki M, Mastalerz-Migas A, Stolarczyk M, Waśko-Czopnik D, Wichniak A. Stanowisko zespołu ekspertów w zakresie diagnostyki i leczenia zespołu jelita nadwrażliwego. Lekarz POZ. 2023;9(6):327-337.
11. Dąbek-Drobny A, Kaczmarczyk O, Woźniakiewicz M et al. Association between Fecal Short-Chain Fatty Acid Levels, Diet, and Body Mass Index in Patients with Inflammatory Bowel Disease. Biology (Basel). 2022; 11(1): 108.
12. Panufnik P, Banasiewicz T, Rydzewska G; Maślan sodu – drogowskazy terapeutyczne. Medycyna Faktów. 2024; 17 (1): 105-112.
13. Lewandowski K, Kaniewska M, Karłowicz K et al. The effectiveness of microencapsulated sodium butyrate at reducing symptoms in patients with irritable bowel syndrome. Prz Gastroenterol. 2022; 17(1): 28-34.
14. Karłowicz K, Lewandowski K, Tulewicz-Marti E et al. P876 Efficacy and safety of microencapsulated butyrate add-on therapy in induction of remission in patients with mild-to-moderate Ulcerative Colitis – results from multi-center, double-blind, randomized, placebo-controlled clinical study. Journal of Crohn’s and Colitis. 2024; 18(1): i1618.
15. Hodgkinson K, El Abbar F, Dobranowski P et al. Butyrate’s role in human health and the current progress towards its clinical application to treat gastrointestinal disease. Clin Nutr. 2023; 42(2): 61-75.
16. Park M, Kwon J, Shin HJ et al. Butyrate enhances the efficacy of radiotherapy via FOXO3A in colorectal cancer patientderived organoids. Int J Oncol. 2020; 57(6): 1307-18.
17. Waśko-Czopnik D. Use of butyric acid in bowel diseases. Lekarz POZ. 2024;10(1):65-69.
18. Skrzydło-Radomańska B, Prozorow-Król B, Cichoż-Lach H et al. The Effectiveness and Safety of Multi-Strain Probiotic Preparation in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Controlled Study. Nutrients. 2021; 13; 756.
19. Skrzydło-Radomańska B, Prozorow-Król B, Cichoż-Lach H et al. The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidobacterium Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant Irritable Bowel Syndrome – A Randomized Double-Blind, Placebo-Controlled Study. Nutrients. 2020; 12: 1999.
2. Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol. 2014; 6: 71-80.
3. Bhattarai Y, Muniz Pedrogo DA, Kashyap PC. Irritable bowel syndrome: A gut microbiota-related disorder? Am J Physiol Gastrointest Liver Physiol. 2017; 312: G52-62.
4. Mari A, Baker FA, Mahamid M et al. The evolving role of gut microbiota in the management of irritable bowel syndrome: An overview of the current knowledge. J Clin Med. 2020; 9: 685.
5. Weiss GA, Hennet T. Mechanisms and consequences of intestinal dysbiosis. Cell Mol Life Sci. 2017; 74: 2959-77.
6. Spiegel BM, Farid M, Esrailian E et al. Is Irritable bowel syndrome a diagnosis of exclusion? A survey of primary care providers, gastroenterologists, and IBS experts. Am J Gastroenterol. 2010; 105: 848-58.
7. Sperber AD, Bangdiwala SI, Drossman DA et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation global study. Gastroenterology. 2020; 160: 99-114.
8. Zhou SY, Gillilland M, Wu X et al. FODMAP diet modulates visceral nociception by lipopolysaccharide-mediated intestinal inflammation and barrier dysfunction. J Clin Investig. 2018; 128: 267-80.
9. Pietrzak A, Skrzydło-Radomańska B, Mulak A et al. Guidelines on the management of irritable bowel syndrome. Gastroenterology Rev. 2018; 13(4): 167-96.
10. Babicki M, Mastalerz-Migas A, Stolarczyk M, Waśko-Czopnik D, Wichniak A. Stanowisko zespołu ekspertów w zakresie diagnostyki i leczenia zespołu jelita nadwrażliwego. Lekarz POZ. 2023;9(6):327-337.
11. Dąbek-Drobny A, Kaczmarczyk O, Woźniakiewicz M et al. Association between Fecal Short-Chain Fatty Acid Levels, Diet, and Body Mass Index in Patients with Inflammatory Bowel Disease. Biology (Basel). 2022; 11(1): 108.
12. Panufnik P, Banasiewicz T, Rydzewska G; Maślan sodu – drogowskazy terapeutyczne. Medycyna Faktów. 2024; 17 (1): 105-112.
13. Lewandowski K, Kaniewska M, Karłowicz K et al. The effectiveness of microencapsulated sodium butyrate at reducing symptoms in patients with irritable bowel syndrome. Prz Gastroenterol. 2022; 17(1): 28-34.
14. Karłowicz K, Lewandowski K, Tulewicz-Marti E et al. P876 Efficacy and safety of microencapsulated butyrate add-on therapy in induction of remission in patients with mild-to-moderate Ulcerative Colitis – results from multi-center, double-blind, randomized, placebo-controlled clinical study. Journal of Crohn’s and Colitis. 2024; 18(1): i1618.
15. Hodgkinson K, El Abbar F, Dobranowski P et al. Butyrate’s role in human health and the current progress towards its clinical application to treat gastrointestinal disease. Clin Nutr. 2023; 42(2): 61-75.
16. Park M, Kwon J, Shin HJ et al. Butyrate enhances the efficacy of radiotherapy via FOXO3A in colorectal cancer patientderived organoids. Int J Oncol. 2020; 57(6): 1307-18.
17. Waśko-Czopnik D. Use of butyric acid in bowel diseases. Lekarz POZ. 2024;10(1):65-69.
18. Skrzydło-Radomańska B, Prozorow-Król B, Cichoż-Lach H et al. The Effectiveness and Safety of Multi-Strain Probiotic Preparation in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Controlled Study. Nutrients. 2021; 13; 756.
19. Skrzydło-Radomańska B, Prozorow-Król B, Cichoż-Lach H et al. The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidobacterium Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant Irritable Bowel Syndrome – A Randomized Double-Blind, Placebo-Controlled Study. Nutrients. 2020; 12: 1999.